                         SEQUENCE LISTING

<110>  Actus
       Blanden, Adam
       Wolfe, Aaron
 
<120>  COMPOSITIONS, METHODS, AND SYSTEMS FOR ORALLY ADMINISTRABLE 
       AFFINITY-BASED PROTEIN

<130>  P274645.WO.01

<150>  62/648,170
<151>  2018-03-26

<160>  5     

<170>  PatentIn version 3.5

<210>  1
<211>  253
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Engineered sequence

<400>  1

Lys Thr Ile Gly Leu Val Ile Ser Thr Leu Asn Asn Pro Phe Phe Val 
1               5                   10                  15      


Thr Leu Lys Asn Gly Ala Glu Glu Lys Ala Lys Glu Leu Gly Tyr Lys 
            20                  25                  30          


Ile Ile Val Glu Asp Ser Gln Asn Asp Ser Ser Lys Glu Leu Ser Asn 
        35                  40                  45              


Val Glu Asp Leu Ile Gln Gln Lys Val Asp Val Leu Leu Ile Asn Pro 
    50                  55                  60                  


Val Asp Ser Asp Ala Val Val Thr Ala Ile Lys Glu Ala Asn Ser Lys 
65                  70                  75                  80  


Asn Ile Pro Val Ile Thr Ile Asp Arg Ser Ala Asn Gly Gly Asp Val 
                85                  90                  95      


Val Ser His Ile Ala Ser Asp Asn Val Lys Gly Gly Glu Met Ala Ala 
            100                 105                 110         


Glu Phe Ile Ala Lys Ala Leu Lys Gly Lys Gly Asn Val Val Glu Leu 
        115                 120                 125             


Glu Gly Ile Pro Gly Ala Ser Ala Ala Arg Asp Arg Gly Lys Gly Phe 
    130                 135                 140                 


Asp Glu Ala Ile Ala Lys Tyr Pro Asp Ile Lys Ile Val Ala Lys Gln 
145                 150                 155                 160 


Ala Ala Asp Phe Asp Arg Ser Lys Gly Leu Ser Val Met Glu Asn Ile 
                165                 170                 175     


Leu Gln Ala Gln Pro Lys Ile Asp Ala Val Phe Ala Gln Asn Asp Glu 
            180                 185                 190         


Met Ala Leu Gly Ala Ile Lys Ala Ile Glu Ala Ala Asn Arg Gln Gly 
        195                 200                 205             


Ile Ile Val Val Gly Phe Asp Gly Thr Glu Asp Ala Leu Lys Ala Ile 
    210                 215                 220                 


Lys Glu Gly Lys Met Ala Ala Thr Ile Ala Gln Gln Pro Ala Leu Met 
225                 230                 235                 240 


Gly Ser Leu Gly Val Glu Met Ala Asp Lys Tyr Leu Lys 
                245                 250             


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Engineered affinithy tag

<400>  2

Asp Tyr Lys Asp Asp Asp Asp Lys 
1               5               


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Engineered sequence

<400>  3

Glu Asn Leu Tyr Phe Gln 
1               5       


<210>  4
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Engiineered sequence

<400>  4

Glu Asn Leu Tyr Phe Ser 
1               5       


<210>  5
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Engineered sequence Nd2 P5A E18A

<400>  5

Lys Ile Ala Asn Phe Ile Pro Ala Glu Leu Lys Leu Ile Thr Lys Ala 
1               5                   10                  15      


Asn Val Gln 
            


